Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 57 | 2024 | 1539 | 6.980 |
Why?
|
Leukemia, Myeloid, Acute | 98 | 2024 | 3606 | 6.060 |
Why?
|
Mastocytosis, Systemic | 12 | 2023 | 102 | 5.170 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 29 | 2024 | 685 | 3.930 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 12 | 2024 | 37 | 2.790 |
Why?
|
Myelodysplastic Syndromes | 29 | 2024 | 1401 | 2.480 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 47 | 2024 | 11708 | 2.150 |
Why?
|
Triazines | 7 | 2023 | 310 | 2.070 |
Why?
|
Antineoplastic Agents | 67 | 2024 | 13629 | 2.040 |
Why?
|
Protein Kinase Inhibitors | 38 | 2024 | 5640 | 1.860 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 381 | 1.790 |
Why?
|
Pyrroles | 11 | 2023 | 1137 | 1.690 |
Why?
|
Pyrimidines | 21 | 2022 | 3011 | 1.650 |
Why?
|
fms-Like Tyrosine Kinase 3 | 18 | 2023 | 496 | 1.540 |
Why?
|
Staurosporine | 9 | 2017 | 242 | 1.500 |
Why?
|
Remission Induction | 41 | 2024 | 2394 | 1.380 |
Why?
|
Asparaginase | 10 | 2024 | 240 | 1.350 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 223 | 1.330 |
Why?
|
Hematologic Neoplasms | 14 | 2024 | 1899 | 1.300 |
Why?
|
Pyrazoles | 10 | 2024 | 1992 | 1.230 |
Why?
|
Cytarabine | 19 | 2024 | 696 | 1.170 |
Why?
|
Mastocytosis | 4 | 2023 | 149 | 1.130 |
Why?
|
Piperazines | 15 | 2016 | 2520 | 1.130 |
Why?
|
Leukemia, Promyelocytic, Acute | 5 | 2020 | 251 | 1.090 |
Why?
|
Sulfonamides | 15 | 2024 | 1973 | 1.010 |
Why?
|
Myeloproliferative Disorders | 11 | 2023 | 612 | 0.960 |
Why?
|
Drug Resistance, Neoplasm | 28 | 2024 | 5230 | 0.920 |
Why?
|
Pyridazines | 6 | 2024 | 200 | 0.900 |
Why?
|
Neoplasm, Residual | 11 | 2024 | 1008 | 0.850 |
Why?
|
Protein-Tyrosine Kinases | 10 | 2018 | 2415 | 0.840 |
Why?
|
Fusion Proteins, bcr-abl | 15 | 2024 | 431 | 0.830 |
Why?
|
Salvage Therapy | 9 | 2022 | 1266 | 0.810 |
Why?
|
Hydroxamic Acids | 5 | 2017 | 482 | 0.810 |
Why?
|
Hematopoietic Stem Cell Transplantation | 23 | 2024 | 5644 | 0.790 |
Why?
|
Glycolipids | 1 | 2022 | 204 | 0.750 |
Why?
|
Drug Substitution | 2 | 2014 | 296 | 0.750 |
Why?
|
Arabinonucleosides | 3 | 2014 | 34 | 0.750 |
Why?
|
Disease-Free Survival | 29 | 2024 | 6830 | 0.740 |
Why?
|
Philadelphia Chromosome | 13 | 2024 | 117 | 0.740 |
Why?
|
Histone Deacetylase Inhibitors | 5 | 2013 | 772 | 0.730 |
Why?
|
Mutation | 43 | 2024 | 29950 | 0.720 |
Why?
|
Thiazoles | 4 | 2014 | 1509 | 0.720 |
Why?
|
Proto-Oncogene Proteins c-kit | 7 | 2022 | 729 | 0.700 |
Why?
|
Recurrence | 30 | 2024 | 8487 | 0.700 |
Why?
|
Cyclopentanes | 2 | 2017 | 89 | 0.680 |
Why?
|
Nitriles | 5 | 2018 | 955 | 0.670 |
Why?
|
Humans | 292 | 2024 | 760261 | 0.660 |
Why?
|
Aniline Compounds | 4 | 2018 | 1068 | 0.640 |
Why?
|
Benzazepines | 1 | 2020 | 311 | 0.620 |
Why?
|
Quinolines | 3 | 2018 | 759 | 0.620 |
Why?
|
Dexamethasone | 3 | 2020 | 1928 | 0.610 |
Why?
|
Leukemia, Myeloid | 9 | 2019 | 696 | 0.610 |
Why?
|
Aged | 112 | 2024 | 168995 | 0.610 |
Why?
|
Maximum Tolerated Dose | 13 | 2022 | 877 | 0.600 |
Why?
|
Benzamides | 12 | 2013 | 1369 | 0.600 |
Why?
|
Enzyme Inhibitors | 10 | 2022 | 3726 | 0.590 |
Why?
|
Leukemia | 9 | 2024 | 1522 | 0.590 |
Why?
|
Adult | 124 | 2024 | 219847 | 0.590 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2022 | 9274 | 0.590 |
Why?
|
Imidazoles | 7 | 2024 | 1178 | 0.580 |
Why?
|
Thrombocythemia, Essential | 2 | 2021 | 107 | 0.580 |
Why?
|
Polycythemia Vera | 3 | 2021 | 159 | 0.580 |
Why?
|
Immunotherapy, Adoptive | 6 | 2023 | 1442 | 0.570 |
Why?
|
Middle Aged | 128 | 2024 | 220175 | 0.560 |
Why?
|
Bone Marrow | 15 | 2024 | 2918 | 0.550 |
Why?
|
Indoles | 6 | 2017 | 1830 | 0.540 |
Why?
|
Janus Kinase 2 | 9 | 2021 | 541 | 0.540 |
Why?
|
Quinazolines | 4 | 2013 | 1363 | 0.500 |
Why?
|
Treatment Outcome | 59 | 2024 | 64947 | 0.490 |
Why?
|
Male | 144 | 2024 | 359413 | 0.470 |
Why?
|
Survival Rate | 29 | 2024 | 12806 | 0.460 |
Why?
|
Female | 142 | 2024 | 391011 | 0.450 |
Why?
|
Recombinant Fusion Proteins | 3 | 2024 | 3735 | 0.450 |
Why?
|
Aged, 80 and over | 51 | 2024 | 58947 | 0.440 |
Why?
|
Thiazolidines | 4 | 2018 | 69 | 0.430 |
Why?
|
Primary Myelofibrosis | 2 | 2013 | 210 | 0.430 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 4 | 2018 | 93 | 0.430 |
Why?
|
Etoposide | 6 | 2022 | 630 | 0.430 |
Why?
|
Niacinamide | 4 | 2024 | 414 | 0.420 |
Why?
|
Hepatic Veno-Occlusive Disease | 4 | 2019 | 221 | 0.410 |
Why?
|
Dose-Response Relationship, Drug | 15 | 2022 | 10829 | 0.410 |
Why?
|
Prognosis | 37 | 2024 | 29636 | 0.410 |
Why?
|
Young Adult | 52 | 2024 | 58673 | 0.410 |
Why?
|
Leukemia, Neutrophilic, Chronic | 2 | 2023 | 13 | 0.390 |
Why?
|
5'-Nucleotidase | 1 | 2013 | 161 | 0.390 |
Why?
|
Mitoxantrone | 3 | 2022 | 149 | 0.390 |
Why?
|
Leukemic Infiltration | 3 | 2018 | 47 | 0.380 |
Why?
|
Transplantation, Homologous | 17 | 2024 | 4814 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 3 | 2016 | 32 | 0.370 |
Why?
|
Antigens, CD19 | 4 | 2023 | 414 | 0.360 |
Why?
|
Anthracyclines | 4 | 2023 | 283 | 0.360 |
Why?
|
Immunoconjugates | 4 | 2024 | 949 | 0.350 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2022 | 2500 | 0.340 |
Why?
|
Azacitidine | 6 | 2024 | 334 | 0.340 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 2 | 2007 | 164 | 0.330 |
Why?
|
Transplantation Conditioning | 8 | 2024 | 1593 | 0.330 |
Why?
|
Molecular Targeted Therapy | 5 | 2023 | 2805 | 0.330 |
Why?
|
Gene Expression Regulation, Leukemic | 6 | 2021 | 645 | 0.330 |
Why?
|
Biphenyl Compounds | 5 | 2018 | 988 | 0.320 |
Why?
|
Apoptosis | 14 | 2019 | 9497 | 0.310 |
Why?
|
Isocitrate Dehydrogenase | 4 | 2024 | 927 | 0.310 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2017 | 2536 | 0.310 |
Why?
|
Survival Analysis | 16 | 2024 | 10185 | 0.300 |
Why?
|
Spinal Nerves | 1 | 2008 | 91 | 0.300 |
Why?
|
Daunorubicin | 7 | 2024 | 155 | 0.300 |
Why?
|
Nucleosides | 1 | 2008 | 131 | 0.300 |
Why?
|
T-Lymphocytes | 9 | 2024 | 10183 | 0.290 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2008 | 133 | 0.290 |
Why?
|
Hypereosinophilic Syndrome | 2 | 2005 | 96 | 0.280 |
Why?
|
Leukemia, Mast-Cell | 2 | 2017 | 13 | 0.270 |
Why?
|
Aminoglycosides | 2 | 2006 | 163 | 0.270 |
Why?
|
Clinical Trials as Topic | 10 | 2024 | 8058 | 0.270 |
Why?
|
Tumor Lysis Syndrome | 2 | 2018 | 38 | 0.270 |
Why?
|
Urate Oxidase | 2 | 2018 | 31 | 0.270 |
Why?
|
Adolescent | 43 | 2024 | 87747 | 0.260 |
Why?
|
Antibodies, Monoclonal | 5 | 2015 | 9196 | 0.260 |
Why?
|
Age Factors | 16 | 2022 | 18415 | 0.260 |
Why?
|
Vincristine | 2 | 2020 | 1038 | 0.250 |
Why?
|
Drug Administration Schedule | 7 | 2014 | 4900 | 0.250 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2021 | 326 | 0.240 |
Why?
|
Bone Marrow Transplantation | 8 | 2016 | 2696 | 0.240 |
Why?
|
Tryptases | 2 | 2023 | 177 | 0.240 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 7 | 2024 | 1408 | 0.240 |
Why?
|
Stem Cell Transplantation | 6 | 2018 | 1601 | 0.240 |
Why?
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2016 | 10 | 0.240 |
Why?
|
Acute Disease | 13 | 2024 | 7268 | 0.230 |
Why?
|
Phenylurea Compounds | 2 | 2018 | 529 | 0.230 |
Why?
|
Mycoses | 2 | 2022 | 387 | 0.230 |
Why?
|
Retrospective Studies | 33 | 2024 | 80301 | 0.220 |
Why?
|
Aminopyridines | 3 | 2017 | 564 | 0.220 |
Why?
|
Glycogen Synthase Kinase 3 | 2 | 2018 | 409 | 0.220 |
Why?
|
Immunophenotyping | 5 | 2021 | 1870 | 0.220 |
Why?
|
Venous Thromboembolism | 4 | 2024 | 1866 | 0.220 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2021 | 629 | 0.210 |
Why?
|
Neutropenia | 3 | 2023 | 884 | 0.210 |
Why?
|
Cytogenetics | 3 | 2010 | 198 | 0.210 |
Why?
|
Administration, Oral | 6 | 2017 | 4044 | 0.210 |
Why?
|
Burkitt Lymphoma | 1 | 2005 | 333 | 0.200 |
Why?
|
Cell Differentiation | 12 | 2021 | 11480 | 0.200 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 3 | 2017 | 352 | 0.200 |
Why?
|
Lymphoma | 3 | 2023 | 1899 | 0.200 |
Why?
|
Nuclear Proteins | 6 | 2024 | 5793 | 0.200 |
Why?
|
Myeloid Cells | 4 | 2015 | 821 | 0.200 |
Why?
|
Neoplasms, Second Primary | 2 | 2024 | 1060 | 0.200 |
Why?
|
Neoplasms | 12 | 2022 | 22066 | 0.200 |
Why?
|
Treatment Failure | 4 | 2019 | 2646 | 0.200 |
Why?
|
Benzimidazoles | 2 | 2018 | 858 | 0.190 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 187 | 0.190 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 3 | 2017 | 367 | 0.190 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 305 | 0.190 |
Why?
|
Cancer Care Facilities | 1 | 2024 | 425 | 0.190 |
Why?
|
Chromosomes, Human, Pair 5 | 3 | 2008 | 385 | 0.190 |
Why?
|
DNA-Binding Proteins | 6 | 2024 | 9590 | 0.190 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 1378 | 0.190 |
Why?
|
Mitochondria | 6 | 2019 | 3598 | 0.190 |
Why?
|
Doxorubicin | 2 | 2020 | 2207 | 0.190 |
Why?
|
Receptor Protein-Tyrosine Kinases | 6 | 2022 | 1614 | 0.180 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2023 | 262 | 0.180 |
Why?
|
Methotrexate | 3 | 2014 | 1717 | 0.180 |
Why?
|
Histones | 5 | 2013 | 2583 | 0.180 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7468 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2021 | 3584 | 0.180 |
Why?
|
Chromosome Deletion | 5 | 2006 | 1387 | 0.180 |
Why?
|
Follow-Up Studies | 16 | 2024 | 39254 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 7 | 2024 | 6545 | 0.170 |
Why?
|
Osteonecrosis | 1 | 2022 | 229 | 0.170 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 316 | 0.170 |
Why?
|
Medical Oncology | 5 | 2024 | 2321 | 0.170 |
Why?
|
Uric Acid | 2 | 2018 | 807 | 0.170 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2017 | 2823 | 0.170 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2015 | 423 | 0.170 |
Why?
|
Cyclophosphamide | 2 | 2020 | 2220 | 0.160 |
Why?
|
Tandem Repeat Sequences | 3 | 2016 | 181 | 0.160 |
Why?
|
Cancer Vaccines | 3 | 2016 | 1044 | 0.160 |
Why?
|
Flow Cytometry | 7 | 2018 | 5873 | 0.160 |
Why?
|
Leukemia, Experimental | 2 | 2016 | 225 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 728 | 0.160 |
Why?
|
Standard of Care | 2 | 2022 | 552 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 7 | 2015 | 4494 | 0.160 |
Why?
|
Bone Marrow Examination | 3 | 2018 | 155 | 0.160 |
Why?
|
Chromosome Aberrations | 3 | 2019 | 1767 | 0.160 |
Why?
|
Hepatitis B | 1 | 2024 | 701 | 0.160 |
Why?
|
Enhancer Elements, Genetic | 3 | 1995 | 1356 | 0.160 |
Why?
|
Galectins | 1 | 2021 | 282 | 0.150 |
Why?
|
Histiocytes | 1 | 2018 | 98 | 0.150 |
Why?
|
Cell Proliferation | 11 | 2021 | 10434 | 0.150 |
Why?
|
Hydrazines | 2 | 2009 | 224 | 0.150 |
Why?
|
Inhibitory Concentration 50 | 4 | 2016 | 465 | 0.150 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2014 | 2874 | 0.150 |
Why?
|
Langerhans Cells | 1 | 2018 | 171 | 0.150 |
Why?
|
Karyotyping | 4 | 2014 | 1172 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 330 | 0.150 |
Why?
|
Mast Cells | 3 | 2023 | 1428 | 0.150 |
Why?
|
Immune Evasion | 1 | 2021 | 362 | 0.150 |
Why?
|
Translocation, Genetic | 5 | 2020 | 1388 | 0.150 |
Why?
|
Arterial Occlusive Diseases | 1 | 2022 | 752 | 0.150 |
Why?
|
Graft vs Host Disease | 6 | 2024 | 3023 | 0.150 |
Why?
|
Immunotherapy | 4 | 2020 | 4637 | 0.140 |
Why?
|
Ubiquitin-Activating Enzymes | 2 | 2015 | 88 | 0.140 |
Why?
|
Cytogenetic Analysis | 3 | 2013 | 271 | 0.140 |
Why?
|
Premedication | 1 | 2018 | 253 | 0.140 |
Why?
|
Eosinophilia | 1 | 2022 | 560 | 0.140 |
Why?
|
Neoplastic Stem Cells | 3 | 2021 | 1347 | 0.140 |
Why?
|
Leukemia, Hairy Cell | 1 | 2017 | 83 | 0.140 |
Why?
|
Methenyltetrahydrofolate Cyclohydrolase | 1 | 2016 | 10 | 0.140 |
Why?
|
Gout Suppressants | 1 | 2018 | 178 | 0.140 |
Why?
|
Geriatric Assessment | 2 | 2015 | 1405 | 0.140 |
Why?
|
Cell Line, Tumor | 15 | 2021 | 16905 | 0.140 |
Why?
|
Leukocytes, Mononuclear | 3 | 2021 | 1828 | 0.130 |
Why?
|
Telomerase | 1 | 2021 | 747 | 0.130 |
Why?
|
Phosphorylation | 10 | 2017 | 8314 | 0.130 |
Why?
|
Proto-Oncogenes | 1 | 2017 | 320 | 0.130 |
Why?
|
U937 Cells | 5 | 2018 | 262 | 0.130 |
Why?
|
Anaphylaxis | 1 | 2023 | 753 | 0.130 |
Why?
|
Leukemia, T-Cell | 1 | 2016 | 101 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2014 | 640 | 0.130 |
Why?
|
RecQ Helicases | 1 | 2015 | 53 | 0.130 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2015 | 4573 | 0.130 |
Why?
|
TYK2 Kinase | 1 | 2015 | 37 | 0.130 |
Why?
|
HL-60 Cells | 5 | 2017 | 363 | 0.130 |
Why?
|
Resorcinols | 1 | 2015 | 41 | 0.130 |
Why?
|
Glomerulonephritis | 1 | 2017 | 337 | 0.130 |
Why?
|
Thrombosis | 3 | 2018 | 3052 | 0.130 |
Why?
|
Tetrahydronaphthalenes | 1 | 2015 | 86 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 185 | 0.120 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2014 | 7 | 0.120 |
Why?
|
Citric Acid Cycle | 1 | 2016 | 230 | 0.120 |
Why?
|
Receptors, Laminin | 1 | 2014 | 26 | 0.120 |
Why?
|
Kidney Glomerulus | 1 | 2017 | 568 | 0.120 |
Why?
|
Tretinoin | 2 | 2020 | 519 | 0.120 |
Why?
|
Granulocyte Precursor Cells | 3 | 2016 | 49 | 0.120 |
Why?
|
Benzodiazepines | 2 | 2018 | 1132 | 0.120 |
Why?
|
Creatine Kinase | 1 | 2017 | 691 | 0.120 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 16 | 0.120 |
Why?
|
Adenine Nucleotides | 1 | 2014 | 111 | 0.120 |
Why?
|
Tumor Cells, Cultured | 8 | 2021 | 6131 | 0.120 |
Why?
|
Sirolimus | 2 | 2014 | 1548 | 0.120 |
Why?
|
Cell Cycle Proteins | 2 | 2024 | 3448 | 0.120 |
Why?
|
bcl-X Protein | 2 | 2014 | 413 | 0.120 |
Why?
|
Signal Transduction | 14 | 2023 | 23363 | 0.120 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 255 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2058 | 0.120 |
Why?
|
Long QT Syndrome | 1 | 2019 | 465 | 0.120 |
Why?
|
Cyclosporins | 2 | 2013 | 216 | 0.120 |
Why?
|
Prescription Fees | 1 | 2015 | 151 | 0.120 |
Why?
|
Receptors, IgG | 1 | 2017 | 565 | 0.120 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 2 | 2024 | 36 | 0.120 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2014 | 87 | 0.110 |
Why?
|
Brain Edema | 1 | 2018 | 603 | 0.110 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2016 | 557 | 0.110 |
Why?
|
Receptor, Notch1 | 2 | 2015 | 495 | 0.110 |
Why?
|
Valine | 1 | 2015 | 409 | 0.110 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2016 | 338 | 0.110 |
Why?
|
Isoxazoles | 1 | 2015 | 230 | 0.110 |
Why?
|
Receptor, Notch2 | 1 | 2014 | 87 | 0.110 |
Why?
|
Mice, SCID | 5 | 2022 | 2627 | 0.110 |
Why?
|
Bone Marrow Cells | 4 | 2021 | 2424 | 0.110 |
Why?
|
Busulfan | 2 | 2021 | 258 | 0.110 |
Why?
|
Refrigeration | 1 | 2013 | 27 | 0.110 |
Why?
|
Gene Frequency | 2 | 2018 | 3605 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2009 | 1591 | 0.110 |
Why?
|
Acetylcysteine | 1 | 2014 | 264 | 0.110 |
Why?
|
Patient Selection | 3 | 2020 | 4276 | 0.110 |
Why?
|
Orthopedics | 1 | 2022 | 891 | 0.110 |
Why?
|
Vidarabine | 2 | 2021 | 336 | 0.110 |
Why?
|
Patient Advocacy | 1 | 2015 | 358 | 0.110 |
Why?
|
Blotting, Western | 7 | 2017 | 5039 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.110 |
Why?
|
Mice | 25 | 2022 | 81216 | 0.100 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2014 | 1067 | 0.100 |
Why?
|
Intention to Treat Analysis | 3 | 2019 | 422 | 0.100 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 267 | 0.100 |
Why?
|
Incidence | 10 | 2024 | 21378 | 0.100 |
Why?
|
Acetylation | 2 | 2013 | 1062 | 0.100 |
Why?
|
Megakaryocytes | 2 | 2015 | 566 | 0.100 |
Why?
|
Combined Modality Therapy | 7 | 2022 | 8551 | 0.100 |
Why?
|
DNA Methylation | 3 | 2024 | 4374 | 0.100 |
Why?
|
src-Family Kinases | 2 | 2017 | 534 | 0.100 |
Why?
|
Single-Cell Analysis | 2 | 2021 | 2368 | 0.100 |
Why?
|
Ribosomal Proteins | 1 | 2014 | 359 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 8498 | 0.100 |
Why?
|
Disease Management | 5 | 2021 | 2508 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2129 | 0.100 |
Why?
|
Mice, Inbred NOD | 5 | 2016 | 1837 | 0.100 |
Why?
|
Drug Eruptions | 1 | 2015 | 335 | 0.100 |
Why?
|
Alternative Splicing | 2 | 2014 | 1091 | 0.100 |
Why?
|
Fertility | 1 | 2016 | 772 | 0.100 |
Why?
|
Specimen Handling | 2 | 2013 | 708 | 0.100 |
Why?
|
Disease Progression | 5 | 2023 | 13505 | 0.100 |
Why?
|
Receptors, Cytokine | 2 | 2009 | 258 | 0.100 |
Why?
|
Embryo, Nonmammalian | 1 | 1995 | 899 | 0.100 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2016 | 1173 | 0.100 |
Why?
|
Animals | 33 | 2022 | 167940 | 0.090 |
Why?
|
Risk Factors | 16 | 2024 | 74269 | 0.090 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 938 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1479 | 0.090 |
Why?
|
Fatal Outcome | 3 | 2018 | 1833 | 0.090 |
Why?
|
Community Networks | 1 | 2013 | 201 | 0.090 |
Why?
|
Physician Assistants | 1 | 2013 | 188 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 995 | 0.090 |
Why?
|
Maytansine | 1 | 2011 | 86 | 0.090 |
Why?
|
Transplantation, Autologous | 3 | 2011 | 2120 | 0.090 |
Why?
|
Lymphadenitis | 1 | 2011 | 98 | 0.090 |
Why?
|
Time Factors | 12 | 2018 | 40133 | 0.090 |
Why?
|
Drug Approval | 1 | 2017 | 816 | 0.090 |
Why?
|
Skin | 2 | 2018 | 4468 | 0.090 |
Why?
|
Central Nervous System | 1 | 2017 | 1334 | 0.090 |
Why?
|
Gene Expression Profiling | 10 | 2019 | 9388 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 2 | 2017 | 2047 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10340 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2014 | 567 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1137 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3929 | 0.090 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4109 | 0.090 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 282 | 0.080 |
Why?
|
Blast Crisis | 2 | 2024 | 101 | 0.080 |
Why?
|
Prednisone | 1 | 2014 | 1566 | 0.080 |
Why?
|
Child | 15 | 2024 | 79758 | 0.080 |
Why?
|
Inflammation Mediators | 2 | 2021 | 1882 | 0.080 |
Why?
|
Neoplasm Staging | 5 | 2020 | 11141 | 0.080 |
Why?
|
Ubiquitins | 1 | 2011 | 370 | 0.080 |
Why?
|
Interleukin-2 | 2 | 2013 | 1890 | 0.080 |
Why?
|
Antigens | 1 | 2015 | 1447 | 0.080 |
Why?
|
Retreatment | 2 | 2021 | 600 | 0.080 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2009 | 886 | 0.080 |
Why?
|
RNA Splicing | 1 | 2013 | 914 | 0.080 |
Why?
|
Combinatorial Chemistry Techniques | 1 | 2009 | 132 | 0.080 |
Why?
|
Mutagenesis, Site-Directed | 3 | 2018 | 1694 | 0.080 |
Why?
|
Candidiasis | 1 | 2011 | 364 | 0.080 |
Why?
|
Liver | 3 | 2017 | 7512 | 0.080 |
Why?
|
RNA Interference | 6 | 2015 | 2846 | 0.080 |
Why?
|
Molecular Biology | 2 | 2023 | 581 | 0.080 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 2008 | 38 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1384 | 0.080 |
Why?
|
Quality of Life | 6 | 2023 | 13300 | 0.080 |
Why?
|
Candida albicans | 1 | 2011 | 378 | 0.080 |
Why?
|
Genomics | 4 | 2019 | 5790 | 0.080 |
Why?
|
JC Virus | 1 | 2008 | 87 | 0.080 |
Why?
|
Serotonin Antagonists | 1 | 2008 | 144 | 0.080 |
Why?
|
Intensive Care Units | 2 | 2019 | 3737 | 0.080 |
Why?
|
RNA, Small Interfering | 5 | 2017 | 3443 | 0.080 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 12968 | 0.070 |
Why?
|
Enzyme Activation | 4 | 2006 | 3604 | 0.070 |
Why?
|
Hospitalization | 2 | 2019 | 10761 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2007 | 79 | 0.070 |
Why?
|
Alu Elements | 1 | 2007 | 115 | 0.070 |
Why?
|
Anticoagulants | 3 | 2020 | 4896 | 0.070 |
Why?
|
Neutrophils | 2 | 2017 | 3770 | 0.070 |
Why?
|
Cell Survival | 6 | 2016 | 5796 | 0.070 |
Why?
|
Genetic Variation | 2 | 2021 | 6540 | 0.070 |
Why?
|
Interleukin-3 | 2 | 2005 | 429 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2753 | 0.070 |
Why?
|
Mutation, Missense | 2 | 2006 | 2563 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1184 | 0.070 |
Why?
|
alpha Catenin | 1 | 2006 | 37 | 0.070 |
Why?
|
Propensity Score | 1 | 2014 | 1918 | 0.070 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2008 | 207 | 0.070 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 2 | 2006 | 105 | 0.070 |
Why?
|
Peptide Fragments | 3 | 2014 | 5120 | 0.070 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2005 | 452 | 0.070 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2008 | 534 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5396 | 0.070 |
Why?
|
Gene Duplication | 1 | 2007 | 314 | 0.070 |
Why?
|
Joints | 1 | 2008 | 321 | 0.070 |
Why?
|
Thrombocytopenia | 3 | 2013 | 1174 | 0.070 |
Why?
|
History, 21st Century | 2 | 2017 | 1576 | 0.070 |
Why?
|
Sacrum | 1 | 2008 | 281 | 0.070 |
Why?
|
Myeloid Progenitor Cells | 1 | 2006 | 114 | 0.070 |
Why?
|
Patient Participation | 1 | 2015 | 1437 | 0.070 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 178 | 0.070 |
Why?
|
Synovial Fluid | 1 | 2008 | 395 | 0.070 |
Why?
|
Isochromosomes | 1 | 2005 | 16 | 0.070 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1892 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2009 | 619 | 0.060 |
Why?
|
Whole-Body Irradiation | 1 | 2006 | 433 | 0.060 |
Why?
|
Sea Urchins | 3 | 1995 | 45 | 0.060 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1188 | 0.060 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2005 | 55 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2017 | 3491 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2017 | 4546 | 0.060 |
Why?
|
Drug Design | 2 | 2011 | 1062 | 0.060 |
Why?
|
Idarubicin | 2 | 2019 | 59 | 0.060 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2005 | 127 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1729 | 0.060 |
Why?
|
Mice, Inbred BALB C | 5 | 2017 | 6226 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5420 | 0.060 |
Why?
|
Drug Monitoring | 3 | 2011 | 966 | 0.060 |
Why?
|
Fatigue | 4 | 2017 | 1544 | 0.060 |
Why?
|
Risk | 2 | 2015 | 9629 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 265 | 0.060 |
Why?
|
Infusions, Intravenous | 4 | 2011 | 2235 | 0.060 |
Why?
|
Comorbidity | 4 | 2015 | 10552 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7400 | 0.060 |
Why?
|
Liposomes | 1 | 2008 | 776 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3360 | 0.060 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2005 | 286 | 0.060 |
Why?
|
Genes, myc | 1 | 2005 | 395 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 141 | 0.060 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 184 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5797 | 0.060 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2004 | 191 | 0.060 |
Why?
|
Myeloablative Agonists | 1 | 2004 | 209 | 0.060 |
Why?
|
Pyridines | 3 | 2015 | 2877 | 0.060 |
Why?
|
Zygote | 2 | 1995 | 115 | 0.060 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2023 | 50 | 0.060 |
Why?
|
Receptors, Notch | 1 | 2008 | 742 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3215 | 0.060 |
Why?
|
Transcription, Genetic | 3 | 2009 | 7593 | 0.050 |
Why?
|
Drug Synergism | 3 | 2015 | 1755 | 0.050 |
Why?
|
Antigens, CD | 2 | 2011 | 4002 | 0.050 |
Why?
|
Tissue Distribution | 3 | 2013 | 2262 | 0.050 |
Why?
|
Boronic Acids | 3 | 2013 | 914 | 0.050 |
Why?
|
Colony-Stimulating Factors | 1 | 2023 | 218 | 0.050 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 482 | 0.050 |
Why?
|
Consensus | 1 | 2013 | 3106 | 0.050 |
Why?
|
Terminal Care | 1 | 2015 | 1759 | 0.050 |
Why?
|
Plasma | 1 | 2006 | 584 | 0.050 |
Why?
|
Recombinant Proteins | 4 | 2013 | 6543 | 0.050 |
Why?
|
Dendritic Cells | 2 | 2023 | 2730 | 0.050 |
Why?
|
Renal Insufficiency | 1 | 2009 | 820 | 0.050 |
Why?
|
Arthritis | 1 | 2008 | 666 | 0.050 |
Why?
|
STAT Transcription Factors | 2 | 2018 | 188 | 0.050 |
Why?
|
Antifungal Agents | 2 | 2022 | 746 | 0.050 |
Why?
|
Cytokines | 3 | 2013 | 7345 | 0.050 |
Why?
|
Recombination, Genetic | 2 | 2007 | 1526 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2927 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2016 | 2014 | 0.050 |
Why?
|
Transcription Factors | 3 | 2017 | 12100 | 0.050 |
Why?
|
Janus Kinases | 2 | 2018 | 250 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 438 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 1737 | 0.050 |
Why?
|
Antibodies, Bispecific | 1 | 2024 | 191 | 0.050 |
Why?
|
E-Selectin | 1 | 2024 | 576 | 0.050 |
Why?
|
Transplantation Chimera | 1 | 2004 | 595 | 0.050 |
Why?
|
RNA, Messenger | 6 | 2015 | 12762 | 0.050 |
Why?
|
Hodgkin Disease | 1 | 2009 | 1381 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 2 | 2006 | 1977 | 0.050 |
Why?
|
Base Sequence | 5 | 2007 | 12447 | 0.050 |
Why?
|
Pyrazines | 3 | 2013 | 1200 | 0.050 |
Why?
|
Phosphoproteins | 2 | 2024 | 2441 | 0.050 |
Why?
|
bcl-Associated Death Protein | 2 | 2015 | 102 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 3159 | 0.050 |
Why?
|
Retinal Neoplasms | 1 | 2003 | 146 | 0.050 |
Why?
|
Point Mutation | 1 | 2006 | 1594 | 0.050 |
Why?
|
Societies, Medical | 3 | 2019 | 3903 | 0.050 |
Why?
|
Gene Amplification | 1 | 2005 | 1085 | 0.050 |
Why?
|
Pharmaceutical Preparations | 1 | 2009 | 1093 | 0.050 |
Why?
|
Histocompatibility | 1 | 2002 | 316 | 0.050 |
Why?
|
Furans | 2 | 2015 | 199 | 0.050 |
Why?
|
Cells, Cultured | 5 | 2019 | 18968 | 0.040 |
Why?
|
Cohort Studies | 6 | 2024 | 41317 | 0.040 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2001 | 430 | 0.040 |
Why?
|
Isoquinolines | 2 | 2016 | 353 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 2007 | 17628 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2002 | 602 | 0.040 |
Why?
|
Protein Isoforms | 2 | 2018 | 1697 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2016 | 717 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2022 | 900 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2022 | 12532 | 0.040 |
Why?
|
Prospective Studies | 9 | 2023 | 54263 | 0.040 |
Why?
|
Piperidines | 1 | 2008 | 1650 | 0.040 |
Why?
|
Genomic Instability | 2 | 2015 | 704 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 675 | 0.040 |
Why?
|
Hematologic Diseases | 2 | 2014 | 497 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2218 | 0.040 |
Why?
|
Logistic Models | 3 | 2019 | 13311 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2013 | 11064 | 0.040 |
Why?
|
Pulmonary Veno-Occlusive Disease | 1 | 2019 | 64 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13249 | 0.040 |
Why?
|
United States | 8 | 2022 | 72363 | 0.040 |
Why?
|
beta Catenin | 2 | 2018 | 1043 | 0.040 |
Why?
|
Genetic Markers | 1 | 2005 | 2608 | 0.040 |
Why?
|
History, 20th Century | 1 | 2006 | 2777 | 0.040 |
Why?
|
Genome-Wide Association Study | 2 | 2017 | 12602 | 0.040 |
Why?
|
Choice Behavior | 1 | 2004 | 817 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2018 | 114 | 0.040 |
Why?
|
Hemorrhage | 2 | 2022 | 3604 | 0.040 |
Why?
|
Resource Allocation | 1 | 2020 | 349 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 3 | 2021 | 3390 | 0.040 |
Why?
|
Expert Testimony | 1 | 2020 | 361 | 0.040 |
Why?
|
World Health Organization | 1 | 2023 | 1319 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2004 | 1765 | 0.040 |
Why?
|
Infant | 5 | 2021 | 36030 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17159 | 0.040 |
Why?
|
Hydrolases | 1 | 2018 | 146 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2018 | 412 | 0.040 |
Why?
|
Phosphorus | 1 | 2018 | 335 | 0.040 |
Why?
|
Immunoglobulin M | 2 | 2014 | 1529 | 0.040 |
Why?
|
Clinical Competence | 1 | 2013 | 4786 | 0.040 |
Why?
|
Body Mass Index | 3 | 2023 | 12901 | 0.040 |
Why?
|
Antithrombins | 1 | 2020 | 313 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 4168 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2017 | 140 | 0.030 |
Why?
|
Cloning, Molecular | 3 | 2005 | 4172 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 2021 | 833 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 776 | 0.030 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2008 | 2776 | 0.030 |
Why?
|
Cell Line | 5 | 2014 | 15626 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 859 | 0.030 |
Why?
|
Child, Preschool | 5 | 2021 | 42034 | 0.030 |
Why?
|
Anxiety | 2 | 2023 | 4532 | 0.030 |
Why?
|
Multiple Myeloma | 2 | 2011 | 5131 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2017 | 14396 | 0.030 |
Why?
|
Proteomics | 1 | 2009 | 3810 | 0.030 |
Why?
|
Pityriasis | 1 | 2015 | 11 | 0.030 |
Why?
|
Dipeptides | 1 | 2018 | 410 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17766 | 0.030 |
Why?
|
Chloramphenicol O-Acetyltransferase | 2 | 1993 | 221 | 0.030 |
Why?
|
Allergens | 1 | 2023 | 1399 | 0.030 |
Why?
|
Folliculitis | 1 | 2015 | 25 | 0.030 |
Why?
|
Hyperuricemia | 1 | 2018 | 224 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
Thiazolidinediones | 1 | 1998 | 465 | 0.030 |
Why?
|
Ichthyosis | 1 | 2015 | 59 | 0.030 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 1999 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2015 | 2866 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2449 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12156 | 0.030 |
Why?
|
Cytoprotection | 1 | 2015 | 200 | 0.030 |
Why?
|
Mice, Inbred C57BL | 4 | 2015 | 22025 | 0.030 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14482 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3707 | 0.030 |
Why?
|
Hydroxyurea | 1 | 2015 | 283 | 0.030 |
Why?
|
Mice, Nude | 2 | 2017 | 3605 | 0.030 |
Why?
|
Europe | 2 | 2013 | 3433 | 0.030 |
Why?
|
Gene Knock-In Techniques | 1 | 2015 | 419 | 0.030 |
Why?
|
Capillaries | 1 | 2017 | 745 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 184 | 0.030 |
Why?
|
Paraproteins | 1 | 2014 | 38 | 0.030 |
Why?
|
Minority Groups | 1 | 2021 | 1199 | 0.030 |
Why?
|
Disease Models, Animal | 5 | 2017 | 18134 | 0.030 |
Why?
|
Survivors | 1 | 2005 | 2367 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2014 | 49 | 0.030 |
Why?
|
Cell Shape | 1 | 2015 | 372 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1791 | 0.030 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 854 | 0.030 |
Why?
|
Models, Biological | 3 | 2019 | 9468 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2004 | 5498 | 0.030 |
Why?
|
Alkylating Agents | 1 | 2014 | 133 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 714 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2018 | 2509 | 0.030 |
Why?
|
Antimetabolites | 1 | 2014 | 127 | 0.030 |
Why?
|
Drug Resistance | 2 | 2014 | 1617 | 0.030 |
Why?
|
Nitrophenols | 1 | 2013 | 169 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 3217 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1149 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2005 | 13456 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1995 | 778 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3613 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2018 | 22041 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2895 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1906 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 1746 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 625 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 2015 | 387 | 0.030 |
Why?
|
Biopsy | 2 | 2018 | 6775 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2012 | 96 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2017 | 788 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2016 | 613 | 0.030 |
Why?
|
Oligonucleotides | 2 | 1993 | 588 | 0.030 |
Why?
|
Microinjections | 1 | 1993 | 321 | 0.030 |
Why?
|
Length of Stay | 2 | 2018 | 6472 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2421 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2005 | 4938 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 372 | 0.020 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 317 | 0.020 |
Why?
|
Ilium | 1 | 2012 | 154 | 0.020 |
Why?
|
Blastocyst | 1 | 1995 | 426 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1194 | 0.020 |
Why?
|
Platelet Count | 1 | 2014 | 777 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 4312 | 0.020 |
Why?
|
Coronary Thrombosis | 1 | 1995 | 486 | 0.020 |
Why?
|
Hematopoiesis | 2 | 2015 | 2063 | 0.020 |
Why?
|
Technology, Pharmaceutical | 1 | 2012 | 84 | 0.020 |
Why?
|
DNA Repair | 1 | 2021 | 2039 | 0.020 |
Why?
|
Sternum | 1 | 2012 | 175 | 0.020 |
Why?
|
Cell Division | 3 | 2006 | 4462 | 0.020 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 151 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1617 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1993 | 1143 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
Stomatitis | 1 | 2014 | 271 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 795 | 0.020 |
Why?
|
Depression | 2 | 2023 | 8033 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2013 | 437 | 0.020 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 525 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8805 | 0.020 |
Why?
|
Secondary Prevention | 2 | 2010 | 1548 | 0.020 |
Why?
|
Bronchial Spasm | 1 | 2011 | 72 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3537 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2015 | 607 | 0.020 |
Why?
|
Fluconazole | 1 | 2011 | 155 | 0.020 |
Why?
|
Antibody Specificity | 1 | 1993 | 1061 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 693 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1705 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 61 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 2755 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 295 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3870 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 616 | 0.020 |
Why?
|
Histone Deacetylase 2 | 1 | 2010 | 72 | 0.020 |
Why?
|
Cell Count | 1 | 2014 | 1838 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1135 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3774 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2019 | 4264 | 0.020 |
Why?
|
Histone Deacetylase 1 | 1 | 2010 | 134 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 719 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1650 | 0.020 |
Why?
|
Physician-Patient Relations | 2 | 2018 | 3242 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8553 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5513 | 0.020 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2015 | 615 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2010 | 162 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4127 | 0.020 |
Why?
|
Decision Making | 2 | 2018 | 3924 | 0.020 |
Why?
|
Harringtonines | 1 | 2008 | 8 | 0.020 |
Why?
|
Fluorouracil | 1 | 2014 | 1630 | 0.020 |
Why?
|
Muramidase | 1 | 2009 | 169 | 0.020 |
Why?
|
Drugs, Investigational | 1 | 2011 | 214 | 0.020 |
Why?
|
DNA Replication | 1 | 2015 | 1412 | 0.020 |
Why?
|
Spleen | 2 | 2006 | 2298 | 0.020 |
Why?
|
Farnesyltranstransferase | 1 | 2008 | 71 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2013 | 1229 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3381 | 0.020 |
Why?
|
Emergencies | 1 | 1995 | 1217 | 0.020 |
Why?
|
Cell Death | 1 | 2013 | 1670 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1446 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1111 | 0.020 |
Why?
|
Genes, abl | 1 | 2008 | 69 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1246 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1395 | 0.020 |
Why?
|
Africa | 1 | 2010 | 707 | 0.020 |
Why?
|
HeLa Cells | 1 | 2014 | 3105 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 884 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1755 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2015 | 7854 | 0.020 |
Why?
|
Metabolomics | 1 | 2017 | 1626 | 0.020 |
Why?
|
Palliative Care | 2 | 2016 | 3607 | 0.020 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 1995 | 1880 | 0.020 |
Why?
|
Risk Assessment | 3 | 2018 | 24086 | 0.020 |
Why?
|
Oxazines | 1 | 2009 | 341 | 0.020 |
Why?
|
Fibrinogen | 1 | 2010 | 887 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2008 | 285 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2525 | 0.020 |
Why?
|
Diarrhea | 1 | 2014 | 1341 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2014 | 2698 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 2014 | 2104 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3278 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3804 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1998 | 2526 | 0.020 |
Why?
|
Morpholines | 1 | 2009 | 583 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9282 | 0.020 |
Why?
|
Pharmacokinetics | 1 | 2006 | 86 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1436 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2015 | 20048 | 0.020 |
Why?
|
Thrombocytosis | 1 | 2006 | 82 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2007 | 1304 | 0.020 |
Why?
|
Binding Sites | 1 | 1995 | 6050 | 0.020 |
Why?
|
Immunotoxins | 1 | 2006 | 175 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2006 | 351 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2011 | 857 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1856 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1344 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3618 | 0.020 |
Why?
|
Gene Library | 1 | 2008 | 1060 | 0.020 |
Why?
|
Tyrphostins | 1 | 2005 | 63 | 0.020 |
Why?
|
Immunoblotting | 1 | 2009 | 1649 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2008 | 749 | 0.020 |
Why?
|
Chromosome Banding | 1 | 2005 | 260 | 0.020 |
Why?
|
Butadienes | 1 | 2005 | 107 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7592 | 0.020 |
Why?
|
Models, Genetic | 2 | 2007 | 3442 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6413 | 0.020 |
Why?
|
Cell Cycle | 1 | 2013 | 2937 | 0.020 |
Why?
|
Tyrosine | 1 | 2009 | 1440 | 0.020 |
Why?
|
Calcium | 1 | 2018 | 5726 | 0.020 |
Why?
|
Genetic Vectors | 2 | 2006 | 3378 | 0.020 |
Why?
|
K562 Cells | 1 | 2006 | 640 | 0.020 |
Why?
|
Protein Conformation | 1 | 1993 | 3969 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2011 | 1439 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 2893 | 0.020 |
Why?
|
Carbazoles | 1 | 2006 | 221 | 0.020 |
Why?
|
Tissue Donors | 2 | 2006 | 2314 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3696 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1993 | 4625 | 0.010 |
Why?
|
Histone Deacetylases | 1 | 2009 | 718 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 2004 | 193 | 0.010 |
Why?
|
Cell Fusion | 1 | 2004 | 293 | 0.010 |
Why?
|
Eye | 1 | 2008 | 710 | 0.010 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2004 | 194 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1993 | 2909 | 0.010 |
Why?
|
Hydrogen Bonding | 1 | 2004 | 291 | 0.010 |
Why?
|
Hospitals, General | 1 | 2008 | 795 | 0.010 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 917 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 2978 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2008 | 718 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9712 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3074 | 0.010 |
Why?
|
Graft Survival | 2 | 2006 | 3793 | 0.010 |
Why?
|
Phosphotyrosine | 1 | 2004 | 456 | 0.010 |
Why?
|
Blood Cell Count | 1 | 2004 | 398 | 0.010 |
Why?
|
Exanthema | 1 | 2008 | 504 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6210 | 0.010 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2004 | 256 | 0.010 |
Why?
|
Tandem Mass Spectrometry | 1 | 2009 | 1190 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3618 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2016 | 3076 | 0.010 |
Why?
|
Stents | 1 | 1995 | 3303 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 488 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2016 | 4739 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15827 | 0.010 |
Why?
|
Retinal Hemorrhage | 1 | 2003 | 95 | 0.010 |
Why?
|
Zinc Fingers | 1 | 2004 | 568 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 815 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 2011 | 912 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2008 | 1354 | 0.010 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2003 | 377 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5206 | 0.010 |
Why?
|
Protein Binding | 1 | 2014 | 9336 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15273 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 4891 | 0.010 |
Why?
|
Serine | 1 | 2005 | 831 | 0.010 |
Why?
|
Topotecan | 1 | 2001 | 132 | 0.010 |
Why?
|
Antigen-Presenting Cells | 1 | 2005 | 967 | 0.010 |
Why?
|
Green Fluorescent Proteins | 1 | 2006 | 2056 | 0.010 |
Why?
|
Liver Diseases | 1 | 2009 | 1301 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12915 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2004 | 1351 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1998 | 6310 | 0.010 |
Why?
|
Fever | 1 | 2008 | 1618 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2007 | 0.010 |
Why?
|
Retroviridae | 1 | 2003 | 850 | 0.010 |
Why?
|
DNA Primers | 1 | 2005 | 2819 | 0.010 |
Why?
|
Coronary Disease | 1 | 1995 | 5993 | 0.010 |
Why?
|
Dyspnea | 1 | 2008 | 1352 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8621 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6181 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2008 | 1189 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2633 | 0.010 |
Why?
|
Lung Diseases | 1 | 2009 | 1915 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2008 | 2204 | 0.010 |
Why?
|
Necrosis | 1 | 2003 | 1612 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3327 | 0.010 |
Why?
|
Pain | 1 | 2014 | 5066 | 0.010 |
Why?
|
Transfection | 1 | 2006 | 5782 | 0.010 |
Why?
|
Chromans | 1 | 1998 | 117 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2005 | 1483 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 6067 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16543 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2004 | 3096 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2013 | 4361 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1675 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2008 | 5201 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3800 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 1663 | 0.010 |
Why?
|
Heart Diseases | 1 | 2009 | 2809 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2010 | 20484 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4292 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2008 | 2277 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 4717 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2009 | 12412 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29725 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2001 | 1328 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 4875 | 0.010 |
Why?
|
Models, Molecular | 1 | 2004 | 5429 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1995 | 11891 | 0.010 |
Why?
|
Visual Acuity | 1 | 2003 | 2635 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7072 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6457 | 0.010 |
Why?
|
Coronary Aneurysm | 1 | 1995 | 233 | 0.010 |
Why?
|
Genome, Human | 1 | 2005 | 4416 | 0.010 |
Why?
|
Ligands | 1 | 1998 | 3277 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 13967 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2011 | 26168 | 0.010 |
Why?
|
Simian virus 40 | 1 | 1989 | 291 | 0.000 |
Why?
|
Deoxyribonuclease I | 1 | 1989 | 224 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11902 | 0.000 |
Why?
|
Chronic Disease | 1 | 2003 | 9283 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 14656 | 0.000 |
Why?
|
Coronary Angiography | 1 | 1995 | 4560 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1989 | 5784 | 0.000 |
Why?
|